Market Cap (In USD)
3.27 Billion
Revenue (In USD)
-
Net Income (In USD)
-54.36 Million
Avg. Volume
1.38 Million
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 11.39-43.73
- PE
- -
- EPS
- -
- Beta Value
- 0.424
- ISIN
- US9250501064
- CUSIP
- 925050106
- CIK
- 1657312
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. David S. Zaccardelli Pharm.D.
- Employee Count
- -
- Website
- https://www.veronapharma.com
- Ipo Date
- 2017-04-28
- Details
- Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.
More Stocks
-
TRM
-
ATISHAYAtishay Limited
ATISHAY
-
VERKVerkkokauppa.com Oyj
VERK
-
PNGZFGCX Metals Limited
PNGZF
-
025860Namhae Chemical Corporation
025860
-
TORVF
-
MNAP
-
GLKFFCleantek Industries Inc.
GLKFF